Trial Profile

Clinical research for anti-CD7 U-CAR-T bridging HST for CD7+ T/NK hematologic malignances: a multicenter, uncontrolled trial

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 25 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GC 027 (Primary)
Indications Haematological malignancies; Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus First in man; Pharmacodynamics; Therapeutic Use

Most Recent Events

10 Apr 2021 Results (n=6) of updated clinical safety and efficacy of GC027 in patients with relapsed/refractory T-cell lymphoblastic leukemia, presented at the 112th Annual Meeting of the American Association for Cancer Research
21 Jun 2020 Results (n=5; as of 6 Feb 2020) assessing clinical safety and preliminary efficacy presented at the 25th Congress of the European Haematology Association
05 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com